To identify patients who are likely to benefit from the PD-1/PD-L1-inhibiting strategy, it is mandatory to comprehensively analyze the individual expression levels of related immune cell markers in the tumor microenvironment. This evidence concerns the gene PDCD1 and neoplasm.